var data={"title":"Endomyocardial fibrosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Endomyocardial fibrosis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/contributors\" class=\"contributor contributor_credentials\">Rebecca Cogswell, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/contributors\" class=\"contributor contributor_credentials\">Nelson B Schiller, MD, FACC, FRCP, FASE</a></dd><dd><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/contributors\" class=\"contributor contributor_credentials\">Harry Acquatella, MD, FACC, FAHA</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/contributors\" class=\"contributor contributor_credentials\">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/contributors\" class=\"contributor contributor_credentials\">Susan B Yeon, MD, JD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 15, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endomyocardial fibrosis (EMF) is a disease of rural poverty that is characterized by fibrosis of the apical endocardium of the right ventricle (RV), left ventricle (LV), or both. The clinical manifestations are largely related to the consequences of restrictive ventricular filling, including left and right sided heart failure.</p><p>EMF refers to a specific syndrome with characteristic epidemiologic features. The epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of EMF are reviewed here. Other cardiomyopathy syndromes with similar pathologies, including hypereosinophilia <span class=\"nowrap\">and/or</span> fibrotic changes of the endocardium are addressed separately. (See <a href=\"topic.htm?path=carcinoid-heart-disease\" class=\"medical medical_review\">&quot;Carcinoid heart disease&quot;</a> and <a href=\"topic.htm?path=hypereosinophilic-syndromes-clinical-manifestations-pathophysiology-and-diagnosis#H15\" class=\"medical medical_review\">&quot;Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis&quot;, section on 'Cardiac disease'</a> and <a href=\"topic.htm?path=treatment-and-prognosis-of-myocarditis-in-adults#H19\" class=\"medical medical_review\">&quot;Treatment and prognosis of myocarditis in adults&quot;, section on 'Eosinophilic myocarditis'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endomyocardial fibrosis (EMF) was first recognized in Uganda during the 1940s and accounts for as much as 20 percent of cardiac cases sent for echocardiography in that country in contemporary series [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Although accurate epidemiologic data are lacking [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/1,3\" class=\"abstract_t\">1,3</a>], EMF is estimated to be the most common form of restrictive cardiomyopathy worldwide.</p><p>Most studies of EMF occur in tropical regions where there is a high prevalence of disease such as Uganda [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/4\" class=\"abstract_t\">4</a>], Nigeria [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/5\" class=\"abstract_t\">5</a>], Ivory Coast, south India [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/6\" class=\"abstract_t\">6</a>], and Brazil [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/7\" class=\"abstract_t\">7</a>]. EMF also occurs in subtropical regions. An echocardiographic screening study in Mozambique found a population prevalence of 20 percent; however, this study included patients with early, subclinical disease [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/8\" class=\"abstract_t\">8</a>]. Within endemic countries, there appears to be a regional variation [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/9,10\" class=\"abstract_t\">9,10</a>]. </p><p>EMF is primarily a disease of the young, occurring in children, adolescents, and young adults. In Uganda, a bimodal peak at ages 10 and 30 has been observed [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/11\" class=\"abstract_t\">11</a>], and a similar pattern was found in Mozambique [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/8\" class=\"abstract_t\">8</a>]. The differences between genders in the frequency of disease have been variable [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/8,11,12\" class=\"abstract_t\">8,11,12</a>]. </p><p class=\"headingAnchor\" id=\"H15162936\"><span class=\"h1\">PATHOPHYSIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The cause of the underlying fibrotic process of endomyocardial fibrosis (EMF) is largely unknown; however, several theories exist and are briefly reviewed.</p><p class=\"headingAnchor\" id=\"H15162944\"><span class=\"h2\">Eosinophilia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Eosinophilia is the most commonly cited etiologic link in EMF. In support of the eosinophilia theory is the observation that EMF resembles a late stage of Loeffler's endocarditis (eosinophilic myocarditis) (<a href=\"image.htm?imageKey=CARD%2F71891\" class=\"graphic graphic_picture graphicRef71891 \">picture 1</a>), a process known to result from sustained eosinophilia in patients with hypereosinophilic syndrome [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/13,14\" class=\"abstract_t\">13,14</a>]. EMF and intraventricular thrombosis have also been observed following a variety of other eosinophilic syndromes including hypersensitivity myocarditis [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/15\" class=\"abstract_t\">15</a>], parasitic infections [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/13,14\" class=\"abstract_t\">13,14</a>], eosinophilic leukemia, sarcoma, carcinoma, and lymphoma [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/16\" class=\"abstract_t\">16</a>], GM-CSF administration [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/17\" class=\"abstract_t\">17</a>], and prolonged drug-induced eosinophilia.</p><p>Despite the similarities between Loeffler&rsquo;s endocarditis and EMF, serum and myocardial eosinophilia have not been consistently demonstrated in EMF. Although one study from Uganda found that 60 percent of patients with EMF had at least mild eosinophilia at the time of diagnosis compared with 10 percent of controls [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/18\" class=\"abstract_t\">18</a>], in Kerala, India, most with EMF did not have active eosinophilia at the time of diagnosis [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/19\" class=\"abstract_t\">19</a>]. Endomyocardial biopsies have not demonstrated eosinophilia in EMF, even in those suspected to have early disease [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/20\" class=\"abstract_t\">20</a>]. It is possible that many with EMF have had significant eosinophilia at one time that is not detected by the time of presentation to medical care.</p><p class=\"headingAnchor\" id=\"H15163013\"><span class=\"h2\">Infectious</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several infections have been implicated in the pathophysiology of EMF, including toxoplasmosis [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/21\" class=\"abstract_t\">21</a>], rheumatic fever [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/22\" class=\"abstract_t\">22</a>], malaria [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/23\" class=\"abstract_t\">23</a>], and helminthic parasites [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/5,24\" class=\"abstract_t\">5,24</a>]. A consistent association with one organism, however, has not been demonstrated. For example, mice infected with plasmodium berghei develop EMF lesions [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/25\" class=\"abstract_t\">25</a>], but a study of a series of 47 African children aged 5 to 15 years old with severe and complicated plasmodium falciparum infection produced insufficient evidence to link these two diseases [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/26\" class=\"abstract_t\">26</a>]. Also opposing the infectious hypothesis is the observation that there are many tropical countries with similar burdens of malaria and filariasis as Uganda and Nigeria that do not have reported cases of EMF.</p><p class=\"headingAnchor\" id=\"H15163102\"><span class=\"h2\">Environmental exposure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Given the regional difference in the frequency of EMF cases and the lack of unifying infectious etiology, the idea of a geochemical basis for EMF has gained popularity. Cerium, a rare earth element, has been postulated to play a role in the pathogenesis of EMF. Cerium is abundant in the soil in areas endemic for the disease and has been shown to induce myocardial fibrosis in rodents [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/19\" class=\"abstract_t\">19</a>]. Serum levels of cerium are high in patients with EMF compared with controls, and it is postulated that cerium is ingested from food and contaminated soil [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/27\" class=\"abstract_t\">27</a>]. The incidence of EMF is decreasing in India, which corresponds with a reduction in soil cerium that has occurred with modernization [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/28\" class=\"abstract_t\">28</a>]. In addition, cerium levels were found to be elevated in the primary teeth of Ugandan children living in regions with a high prevalence of EMF when compared with children from the United Kingdom [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/29\" class=\"abstract_t\">29</a>]. </p><p>Cassava is consumed extensively in some tropical African and Latin American countries. It contains linamarin, which may liberate cyanide in the gut. A low-protein diet diminishes the detoxification of cyanide, which may affect myocardial cell function. In animal models, cassava intake may induce interstitial fibrosis, intracellular vacuoles, and endocardial thickening in the absence of parasites or eosinophilia [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/30,31\" class=\"abstract_t\">30,31</a>]. The relationship between cassava and EMF warrants further investigation [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/32\" class=\"abstract_t\">32</a>].</p><p class=\"headingAnchor\" id=\"H15163159\"><span class=\"h2\">Immunologic</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The presence of anti-myosin autoantibodies has been demonstrated in EMF; however, these antibodies can be detected in other forms of heart disease such as Dressler&rsquo;s syndrome, rheumatic heart disease, and in patients with post-transplant rejection [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/33\" class=\"abstract_t\">33</a>].</p><p class=\"headingAnchor\" id=\"H15163186\"><span class=\"h2\">Genetic</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A familial link has been identified in many studies; however, it is not known whether this is due to an environmental or genetic cause or both [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/8,34\" class=\"abstract_t\">8,34</a>]. </p><p class=\"headingAnchor\" id=\"H15163214\"><span class=\"h1\">PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In endomyocardial fibrosis (EMF), there is fibrosis of the right <span class=\"nowrap\">and/or</span> left apical endocardial surfaces that leads to restrictive physiology [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/35\" class=\"abstract_t\">35</a>]. Additionally, tethering of the atrioventricular (AV) valve papillary muscles <span class=\"nowrap\">and/or&nbsp;fibrosis</span> of the respective ventricular inflow tracts leads to significant AV valve regurgitation. Gross pathology reveals ventricular endocardial thickening and fibrosis often with overlying thrombus. The atrium of the affected ventricle is often dramatically enlarged (<a href=\"image.htm?imageKey=CARD%2F53361\" class=\"graphic graphic_diagnosticimage graphicRef53361 \">image 1</a>) with reduced ventricular volumes. Histopathology demonstrates increased type I collagen deposition, subendocardial infarction, fibrosis, and thrombus [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/10,36\" class=\"abstract_t\">10,36</a>]. In many pathology studies, there is a lack of inflammation or eosinophilia, implying that at end-stage disease, the inflammatory process is inactive [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/37\" class=\"abstract_t\">37</a>]. </p><p class=\"headingAnchor\" id=\"H15163271\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical manifestations of endomyocardial fibrosis (EMF) are largely related to the presence of right <span class=\"nowrap\">and/or</span> left heart failure. Patients may report dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, lower extremity, and abdominal swelling. A history of a febrile illness with or without urticaria is occasionally obtained [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/38\" class=\"abstract_t\">38</a>]. </p><p>In Africans with EMF in particular, there is often dramatic ascites, which may or may not be accompanied by other signs of right-sided heart failure, such as elevated jugular venous pressure <span class=\"nowrap\">and/or</span> lower extremity edema [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/39-42\" class=\"abstract_t\">39-42</a>]. The high prevalence of malnutrition and hypoalbuminemia may explain the predilection for ascites in this population. In one series, the ascitic fluid protein content was described as exudative in 35 of 47 patients with EMF, and the authors concluded that an inflammatory process might also be contributing [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/40\" class=\"abstract_t\">40</a>]. The serum albumin to ascites gradient (which is a more accurate indicator of portal hypertension such as my result from heart failure) was not reported. (See <a href=\"topic.htm?path=evaluation-of-adults-with-ascites#H56451750\" class=\"medical medical_review\">&quot;Evaluation of adults with ascites&quot;, section on 'Determining the cause of the ascites'</a>.)</p><p>Patients with EMF often also have large pleural and pericardial effusions. Severe atrial enlargement leads to the appearance of cardiomegaly on chest radiography. Atrial fibrillation is common in end-stage disease and predicts a poor prognosis [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H15163383\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H15163391\"><span class=\"h2\">Echocardiography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although clinically similar to Loffler&rsquo;s endocarditis, the diagnosis of endomyocardial fibrosis (EMF) should be reserved for patients from endemic regions without a clearly identified cause for sustained eosinophilia with the classic echocardiography features listed below [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/44-46\" class=\"abstract_t\">44-46</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Apical fibrosis of the right ventricle (RV), left ventricle (LV), or both ventricles<strong> </strong>(<a href=\"image.htm?imageKey=CARD%2F60129\" class=\"graphic graphic_diagnosticimage graphicRef60129 \">image 2</a> and <a href=\"image.htm?imageKey=CARD%2F59830\" class=\"graphic graphic_figure graphicRef59830 \">figure 1</a>)<strong>.</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tethering the atrioventricular (AV) valve papillary muscles, leading to mitral <span class=\"nowrap\">and/or</span> tricuspid regurgitation (<a href=\"image.htm?imageKey=CARD%2F53361\" class=\"graphic graphic_diagnosticimage graphicRef53361 \">image 1</a>).<strong> </strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Giant atrial enlargement (<a href=\"image.htm?imageKey=CARD%2F53361\" class=\"graphic graphic_diagnosticimage graphicRef53361 \">image 1</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Restrictive filling pattern on Doppler recordings of mitral valve inflow (<a href=\"image.htm?imageKey=CARD%2F68541\" class=\"graphic graphic_waveform graphicRef68541 \">waveform 1</a>).<strong> </strong></p><p/><p>In addition, apical thrombi are often present (<a href=\"image.htm?imageKey=CARD%2F80830\" class=\"graphic graphic_diagnosticimage graphicRef80830 \">image 3</a>). When available, administration of microbubble echocardiographic contrast agent should be considered to identify and define the extent of apical thrombus (see <a href=\"topic.htm?path=contrast-echocardiography-clinical-applications#H7\" class=\"medical medical_review\">&quot;Contrast echocardiography: Clinical applications&quot;, section on 'Endocardial border definition'</a>). In EMF, the apex maintains inward systolic contractile motion that may help to differentiate EMF from other causes of apical thrombi associated with an akinetic or dyskinetic apex such as myocardial infarction or Chagas disease [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/46\" class=\"abstract_t\">46</a>] (<a href=\"image.htm?imageKey=CARD%2F59830\" class=\"graphic graphic_figure graphicRef59830 \">figure 1</a>). </p><p>An echocardiographic screening study in Mozambique included echocardiographic criteria for the diagnosis and staging of EMF [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/8\" class=\"abstract_t\">8</a>]. As the natural history of EMF is not well defined, these criteria will likely aid in defining the stages of this disease and in determining the clinical significance of early EMF.</p><p class=\"headingAnchor\" id=\"H15163473\"><span class=\"h2\">Cardiac catheterization</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cardiac catheterization is not required for the diagnosis of EMF. However, on hemodynamic studies, a restrictive pattern is observed with diastolic dip and plateau pressure tracings. Depending on the ventricle involved, mitral and tricuspid regurgitation may be demonstrated. Ventricular angiography reveals apical obliteration of the affected ventricle (<a href=\"image.htm?imageKey=CARD%2F60129\" class=\"graphic graphic_diagnosticimage graphicRef60129 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/47\" class=\"abstract_t\">47</a>].</p><p class=\"headingAnchor\" id=\"H15163497\"><span class=\"h2\">Cardiovascular magnetic resonance imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cardiovascular magnetic resonance (CMR) imaging with contrast demonstrates myocardial fibrosis (<a href=\"image.htm?imageKey=CARD%2F80830\" class=\"graphic graphic_diagnosticimage graphicRef80830 \">image 3</a>) [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/48,49\" class=\"abstract_t\">48,49</a>]. In a series of 36 patients with EMF, patients with fibrous tissue deposition identified by late gadolinium enhancement cardiac magnetic resonance imaging indexed to body surface area <span class=\"nowrap\">(FT/BSA)</span> of &gt;19 <span class=\"nowrap\">mL/m<sup>2</sup>,</span> had increased mortality rate, worse New York Heart Association functional class, and increased likelihood of surgery [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/50\" class=\"abstract_t\">50</a>]. However, the utility of this information in addition to echocardiography is unclear, and this modality is generally unavailable in areas with the highest burden of disease. In early disease where there is suspicion for active inflammation, CMR may be useful in identifying patients who may benefit from steroid therapy. (See <a href=\"topic.htm?path=clinical-utility-of-cardiovascular-magnetic-resonance-imaging#H36992798\" class=\"medical medical_review\">&quot;Clinical utility of cardiovascular magnetic resonance imaging&quot;, section on 'Late gadolinium enhancement'</a>.) </p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">PROGNOSIS AND MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The natural history of endomyocardial fibrosis (EMF) is not fully defined, and there are few data available to guide therapeutic decisions. Most present to medical care with end-stage disease and suffer an annual mortality as high as 25 percent despite medical treatment [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/43,51\" class=\"abstract_t\">43,51</a>]. Surgical management has led to long-term survival in some patients with EMF [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/7\" class=\"abstract_t\">7</a>]; however, this option is unavailable in regions with a high disease burden.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Medical therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Available literature is limited to case series that do not fully define treatment regimens [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/43,51\" class=\"abstract_t\">43,51</a>]. A general approach can be extrapolated from the treatment of patients with heart failure due to restrictive diastolic dysfunction from other causes. (See <a href=\"topic.htm?path=treatment-and-prognosis-of-heart-failure-with-preserved-ejection-fraction\" class=\"medical medical_review\">&quot;Treatment and prognosis of heart failure with preserved ejection fraction&quot;</a> and <a href=\"topic.htm?path=definition-and-classification-of-the-cardiomyopathies#H8\" class=\"medical medical_review\">&quot;Definition and classification of the cardiomyopathies&quot;, section on 'Restrictive cardiomyopathy'</a>.)</p><p>Diuretics and rate control for atrial fibrillation are currently the mainstays of therapy.</p><p>Pleural, pericardial, or ascitic fluid removal may alleviate symptoms, but these often reaccumulate. In patients with suspected acute carditis, <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> may be of benefit. (See <a href=\"topic.htm?path=treatment-and-prognosis-of-myocarditis-in-adults#H19\" class=\"medical medical_review\">&quot;Treatment and prognosis of myocarditis in adults&quot;, section on 'Eosinophilic myocarditis'</a>.) </p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endomyocardial resection with valve replacement or repair has gained prominence at many centers, especially in subjects in advanced heart failure [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/7,50,52,53\" class=\"abstract_t\">7,50,52,53</a>]. Immediate postoperative mortality is high, ranging from 15 to 30 percent, but surgery offers the possibility of long-term survival [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/7,53\" class=\"abstract_t\">7,53</a>]. Published series have been small, controlled data are lacking, and overall experience is limited. Questions remain about the appropriate timing, perioperative mortality, and long-term prognosis (<a href=\"image.htm?imageKey=CARD%2F53361\" class=\"graphic graphic_diagnosticimage graphicRef53361 \">image 1</a> and <a href=\"image.htm?imageKey=CARD%2F60677\" class=\"graphic graphic_diagnosticimage graphicRef60677 \">image 4</a>). Cardiac surgery is not routinely available in areas with high EMF prevalence. </p><p>A surgical series of 83 patients with EMF from Brazil with mean age 31 years (range 4 to 59) and New York Heart Association functional class III to IV symptoms had a survival probability of 55 percent at 17 years [<a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/7\" class=\"abstract_t\">7</a>]. There were 15 late deaths (six unrelated to EMF) during mean 7.7-year follow-up. Four patients were reoperated on for recurrent fibrosis, five patients were reoperated on for native or prosthetic valve disease, and in six patients, EMF appeared in the other ventricle.</p><p class=\"headingAnchor\" id=\"H29222886\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Endomyocardial fibrosis (EMF) is a restrictive cardiomyopathy observed in the tropics usually at the end-stage of the disease. It may be indistinguishable from Loeffler&rsquo;s endocarditis, observed in temperate climates.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The pathogenesis remains unknown; however, eosinophilia may play a role.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Echocardiography may show uni- or bilateral ventricular apex obliteration with severely dilated atria and a restrictive filling pattern.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The prognosis is poor, with a mortality estimated at 25 percent per year. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Limited data suggest that surgical treatment with endomyocardial resection and valve replacement may be beneficial in patients with advanced apical obliteration and severe heart failure symptoms; however, this option is largely unavailable where the disease is present.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/1\" class=\"nounderline abstract_t\">Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 2005; 112:3577.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/2\" class=\"nounderline abstract_t\">BALL JD, WILLIAMS AW, DAVIES JN. Endomyocardial fibrosis. Lancet 1954; 266:1049.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/3\" class=\"nounderline abstract_t\">Grimaldi A, Mocumbi AO, Freers J, et al. Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. Circulation 2016; 133:2503.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/4\" class=\"nounderline abstract_t\">Connor DH, Somers K, Hutt MS, et al. Endomyocardial fibrosis in Uganda (Davies' disease). 1. An epidemiologic, clinical, and pathologic study. Am Heart J 1967; 74:687.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/5\" class=\"nounderline abstract_t\">Andy JJ, Ogunowo PO, Akpan NA, et al. Helminth associated hypereosinophilia and tropical endomyocardial fibrosis (EMF) in Nigeria. Acta Trop 1998; 69:127.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/6\" class=\"nounderline abstract_t\">Valiathan MS, Balakrishnan KG, Sankarkumar R, Kartha CC. Surgical treatment of endomyocardial fibrosis. Ann Thorac Surg 1987; 43:68.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/7\" class=\"nounderline abstract_t\">Moraes F, Lapa C, Hazin S, et al. Surgery for endomyocardial fibrosis revisited. Eur J Cardiothorac Surg 1999; 15:309.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/8\" class=\"nounderline abstract_t\">Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH. A population study of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med 2008; 359:43.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/9\" class=\"nounderline abstract_t\">Kutty VR, Abraham S, Kartha CC. Geographical distribution of endomyocardial fibrosis in south Kerala. Int J Epidemiol 1996; 25:1202.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/10\" class=\"nounderline abstract_t\">Radhakumary C, Kumari TV, Kartha CC. Endomyocardial fibrosis is associated with selective deposition of type I collagen. Indian Heart J 2001; 53:486.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/11\" class=\"nounderline abstract_t\">Rutakingirwa M, Ziegler JL, Newton R, Freers J. Poverty and eosinophilia are risk factors for endomyocardial fibrosis (EMF) in Uganda. Trop Med Int Health 1999; 4:229.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/12\" class=\"nounderline abstract_t\">Falase AO. Endomyocardial fibrosis in Africa. Postgrad Med J 1983; 59:170.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/13\" class=\"nounderline abstract_t\">Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759.</a></li><li class=\"breakAll\">Spry CJF. A Comprehensive Review and Guide to the Scientific and Medical Literature, Oxford Medical Publications, Oxford 1988.</li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/15\" class=\"nounderline abstract_t\">Kendell KR, Day JD, Hruban RH, et al. Intimate association of eosinophils to collagen bundles in eosinophilic myocarditis and ranitidine-induced hypersensitivity myocarditis. Arch Pathol Lab Med 1995; 119:1154.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/16\" class=\"nounderline abstract_t\">Monsuez JJ, de Kerviler E, Barboteu M, et al. Non-Hodgkin's lymphoma related eosinophilic endomyocardial disease. Eur Heart J 1994; 15:1423.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/17\" class=\"nounderline abstract_t\">Donhuijsen K, Haedicke C, Hattenberger S, et al. Granulocyte-macrophage colony-stimulating factor-related eosinophilia and Loeffler's endocarditis. Blood 1992; 79:2798.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/18\" class=\"nounderline abstract_t\">Freers J, Masembe V, Schmauz R, Mayanja-Kizza H. Endomyocardial fibrosis syndrome in Uganda. Lancet 2000; 355:1994.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/19\" class=\"nounderline abstract_t\">Valiathan SM, Kartha CC. Endomyocardial fibrosis--the possible connexion with myocardial levels of magnesium and cerium. Int J Cardiol 1990; 28:1.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/20\" class=\"nounderline abstract_t\">Patel AK, Ziegler JL, D'Arbela PG, Somers K. Familial cases of endomyocardial fibrosis in Uganda. Br Med J 1971; 4:331.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/21\" class=\"nounderline abstract_t\">Ijaola O, Falase AO. Distribution of antibodies against Coxsackie B viruses, arboviruses and Toxoplasma gondii among patients with endomyocardial fibrosis (EMF) compared with normal subjects from EMF endemic and non-endemic zones of Nigeria. Afr J Med Med Sci 1990; 19:93.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/22\" class=\"nounderline abstract_t\">Shaper AG. Endomyocardial fibrosis and rheumatic heart-disease. Lancet 1966; 1:639.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/23\" class=\"nounderline abstract_t\">Eling WM, Jerusalem CR, Heinen-Borries UJ, et al. Is malaria involved in the pathogenesis of tropical endomyocardial fibrosis? Acta Leiden 1988; 57:47.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/24\" class=\"nounderline abstract_t\">Ive FA, Willis AJ, Ikeme AC, Brockington IF. Endomyocardial fibrosis and filariasis. Q J Med 1967; 36:495.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/25\" class=\"nounderline abstract_t\">Eling WM, Jerusalem CR, Heinen-Borries U. Role of macrophages in the pathogenesis of endomyocardial fibrosis in murine malaria. Trans R Soc Trop Med Hyg 1984; 78:43.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/26\" class=\"nounderline abstract_t\">Mocumbi AO, Songane M, Salom&atilde;o C, et al. Lack of evidence of myocardial damage in children with Plasmodium falciparum severe and complicated malaria from an endemic area for endomyocardial fibrosis. J Trop Pediatr 2011; 57:312.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/27\" class=\"nounderline abstract_t\">Eapen JT, Kartha CC, Rathinam K, Valiathan MS. Levels of cerium in the tissues of rats fed a magnesium-restricted and cerium-adulterated diet. Bull Environ Contam Toxicol 1996; 56:178.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/28\" class=\"nounderline abstract_t\">Sivasankaran S. Restrictive cardiomyopathy in India: the story of a vanishing mystery. Heart 2009; 95:9.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/29\" class=\"nounderline abstract_t\">Brown CJ, Chenery SR, Smith B, et al. Environmental influences on the trace element content of teeth--implications for disease and nutritional status. Arch Oral Biol 2004; 49:705.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/30\" class=\"nounderline abstract_t\">Sezi CL. Effects of cassava diet on Cercopithecus aethiops livers: a case for cassava as the cause of both tropical splenomegaly syndrome (TSS) and endomyocardial fibrosis (EMF). East Afr Med J 1996; 73:S24.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/31\" class=\"nounderline abstract_t\">Sezi CL. Effect of protein deficient cassava diet on Cercopithecus aethiops hearts and its possible role in the aetiology and pathogenesis of endomyocardial fibrosis in man. East Afr Med J 1996; 73:S11.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/32\" class=\"nounderline abstract_t\">Chelo D, Nguefack F, Mbassi Awa HD, Kingue S. Endomyocardial fibrosis in Sub Saharan Africa: The geographical origin, socioeconomic status, and dietary habits of cases reported in Yaounde, Cameroon. Ann Pediatr Cardiol 2015; 8:202.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/33\" class=\"nounderline abstract_t\">Mocumbi AO, Latif N, Yacoub MH. Presence of circulating anti-myosin antibodies in endomyocardial fibrosis. PLoS Negl Trop Dis 2010; 4:e661.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/34\" class=\"nounderline abstract_t\">Lowenthal MN. Endomyocardial fibrosis: familial and other cases from northern Zambia. Med J Zambia 1978; 12:2.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/35\" class=\"nounderline abstract_t\">Connor DH, Somers K, Hutt MS, et al. Endomyocardial fibrosis in Uganda (Davies' disease). II. An epidemiologic, clinical, and pathologic study. Am Heart J 1968; 75:107.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/36\" class=\"nounderline abstract_t\">Mocumbi AO, Yacoub MH, Yokohama H, Ferreira MB. Right ventricular endomyocardial fibrosis. Cardiovasc Pathol 2009; 18:64.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/37\" class=\"nounderline abstract_t\">Chopra P, Narula J, Talwar KK, et al. Histomorphologic characteristics of endomyocardial fibrosis: an endomyocardial biopsy study. Hum Pathol 1990; 21:613.</a></li><li class=\"breakAll\">Freers J, Hakim J, Myanja-Kizza H, Parry E. The Heart. In: Principles of Medicine in Africa, Parry E, Godfrey R, Mabey D, Gill G (Eds), Cambridge University Press, Cambridge 2004. p.837.</li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/39\" class=\"nounderline abstract_t\">Freers J, Mayanja-Kizza H, Rutakingirwa M, Gerwing E. Endomyocardial fibrosis: why is there striking ascites with little or no peripheral oedema? Lancet 1996; 347:197.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/40\" class=\"nounderline abstract_t\">Barretto AC, Mady C, Oliveira SA, et al. Clinical meaning of ascites in patients with endomyocardial fibrosis. Arq Bras Cardiol 2002; 78:196.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/41\" class=\"nounderline abstract_t\">Marijon E, Hausse AO, Ferreira B. Typical clinical aspect of endomyocardial fibrosis. Int J Cardiol 2006; 112:259.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/42\" class=\"nounderline abstract_t\">Guimar&atilde;es AC, Esteves JP, Filho AS, Macedo V. Clinical aspects of endomyocardial fibrosis in Bahia, Brazil. Am Heart J 1971; 81:7.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/43\" class=\"nounderline abstract_t\">Barretto AC, Mady C, Nussbacher A, et al. Atrial fibrillation in endomyocardial fibrosis is a marker of worse prognosis. Int J Cardiol 1998; 67:19.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/44\" class=\"nounderline abstract_t\">Berensztein CS, Pi&ntilde;eiro D, Marcotegui M, et al. Usefulness of echocardiography and doppler echocardiography in endomyocardial fibrosis. J Am Soc Echocardiogr 2000; 13:385.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/45\" class=\"nounderline abstract_t\">Hassan WM, Fawzy ME, Al Helaly S, et al. Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic findings in endomyocardial fibrosis: a 25-year experience. Chest 2005; 128:3985.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/46\" class=\"nounderline abstract_t\">Acquatella H, Schiller NB, Puigb&oacute; JJ, et al. Value of two-dimensional echocardiography in endomyocardial disease with and without eosinophilia. A clinical and pathologic study. Circulation 1983; 67:1219.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/47\" class=\"nounderline abstract_t\">Barretto AC, da Luz PL, de Oliveira SA, et al. Determinants of survival in endomyocardial fibrosis. Circulation 1989; 80:I177.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/48\" class=\"nounderline abstract_t\">Qureshi N, Amin F, Chatterjee D, et al. MR imaging of endomyocardial fibrosis (EMF). Int J Cardiol 2011; 149:e36.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/49\" class=\"nounderline abstract_t\">Smedema JP, Winckels SK, Snoep G, et al. Tropical endomyocardial fibrosis (Davies' disease): case report demonstrating the role of magnetic resonance imaging. Int J Cardiovasc Imaging 2004; 20:517.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/50\" class=\"nounderline abstract_t\">Salemi VM, Rochitte CE, Shiozaki AA, et al. Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients. Circ Cardiovasc Imaging 2011; 4:304.</a></li><li class=\"breakAll\">Wynne J, Braunwald E.. The Cardiomyopathies. In: Braunwald's Heart Disease, Zipes DP, Libby P, Bonow RO, Braunwald E (Eds), Elsevier Saunders, Philadeplhia 2005. p.1659.</li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/52\" class=\"nounderline abstract_t\">Schneider U, Jenni R, Turina J, et al. Long-term follow up of patients with endomyocardial fibrosis: effects of surgery. Heart 1998; 79:362.</a></li><li><a href=\"https://www.uptodate.com/contents/endomyocardial-fibrosis/abstract/53\" class=\"nounderline abstract_t\">Mocumbi AO, Yacoub S, Yacoub MH. Neglected tropical cardiomyopathies: II. Endomyocardial fibrosis: myocardial disease. Heart 2008; 94:384.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4927 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H29222886\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H15162936\" id=\"outline-link-H15162936\">PATHOPHYSIOLOGY</a><ul><li><a href=\"#H15162944\" id=\"outline-link-H15162944\">Eosinophilia</a></li><li><a href=\"#H15163013\" id=\"outline-link-H15163013\">Infectious</a></li><li><a href=\"#H15163102\" id=\"outline-link-H15163102\">Environmental exposure</a></li><li><a href=\"#H15163159\" id=\"outline-link-H15163159\">Immunologic</a></li><li><a href=\"#H15163186\" id=\"outline-link-H15163186\">Genetic</a></li></ul></li><li><a href=\"#H15163214\" id=\"outline-link-H15163214\">PATHOLOGY</a></li><li><a href=\"#H15163271\" id=\"outline-link-H15163271\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H15163383\" id=\"outline-link-H15163383\">DIAGNOSIS</a><ul><li><a href=\"#H15163391\" id=\"outline-link-H15163391\">Echocardiography</a></li><li><a href=\"#H15163473\" id=\"outline-link-H15163473\">Cardiac catheterization</a></li><li><a href=\"#H15163497\" id=\"outline-link-H15163497\">Cardiovascular magnetic resonance imaging</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">PROGNOSIS AND MANAGEMENT</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Medical therapy</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Surgery</a></li></ul></li><li><a href=\"#H29222886\" id=\"outline-link-H29222886\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/4927|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/53361\" class=\"graphic graphic_diagnosticimage\">- Endomyocard fibros RA echo</a></li><li><a href=\"image.htm?imageKey=CARD/60129\" class=\"graphic graphic_diagnosticimage\">- Endomyocard fibrosis echo</a></li><li><a href=\"image.htm?imageKey=CARD/80830\" class=\"graphic graphic_diagnosticimage\">- CMR of eosinophilic endomyocardial fibrosis</a></li><li><a href=\"image.htm?imageKey=CARD/60677\" class=\"graphic graphic_diagnosticimage\">- Endomyocard fibrosis surg</a></li></ul></li><li><div id=\"CARD/4927|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/59830\" class=\"graphic graphic_figure\">- Schematic of echo findings in EMF</a></li></ul></li><li><div id=\"CARD/4927|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/71891\" class=\"graphic graphic_picture\">- Acute eosinophilic myocarditis</a></li></ul></li><li><div id=\"CARD/4927|Waveform\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"WAVEFORMS\">WAVEFORMS</a></div><ul><li><a href=\"image.htm?imageKey=CARD/68541\" class=\"graphic graphic_waveform\">- Doppler restrictive CM I</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=carcinoid-heart-disease\" class=\"medical medical_review\">Carcinoid heart disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-utility-of-cardiovascular-magnetic-resonance-imaging\" class=\"medical medical_review\">Clinical utility of cardiovascular magnetic resonance imaging</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=contrast-echocardiography-clinical-applications\" class=\"medical medical_review\">Contrast echocardiography: Clinical applications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=definition-and-classification-of-the-cardiomyopathies\" class=\"medical medical_review\">Definition and classification of the cardiomyopathies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-adults-with-ascites\" class=\"medical medical_review\">Evaluation of adults with ascites</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypereosinophilic-syndromes-clinical-manifestations-pathophysiology-and-diagnosis\" class=\"medical medical_review\">Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-heart-failure-with-preserved-ejection-fraction\" class=\"medical medical_review\">Treatment and prognosis of heart failure with preserved ejection fraction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-myocarditis-in-adults\" class=\"medical medical_review\">Treatment and prognosis of myocarditis in adults</a></li></ul></div></div>","javascript":null}